700 related articles for article (PubMed ID: 28380487)
1. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria.
Kolkhir P; Altrichter S; Hawro T; Maurer M
Allergy; 2018 Apr; 73(4):940-948. PubMed ID: 29130488
[TBL] [Abstract][Full Text] [Related]
4. D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
Asero R; Marzano AV; Ferrucci S; Cugno M
Int Arch Allergy Immunol; 2017; 172(1):40-44. PubMed ID: 28219067
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
6. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
8. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria.
de Montjoye L; Darrigade AS; Giménez-Arnau A; Herman A; Dumoutier L; Baeck M
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):55-66. PubMed ID: 31965967
[No Abstract] [Full Text] [Related]
9. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
10. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
11. Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life.
Larrea-Baca I; Gurpegui-Resano M
Enferm Clin; 2017; 27(6):361-368. PubMed ID: 28457893
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
Finlay AY; Kaplan AP; Beck LA; Antonova EN; Balp MM; Zazzali J; Khalil S; Maurer M
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1715-1721. PubMed ID: 28573683
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of Autologous Whole Blood Injection Efficacy in Patients with Chronic Spontaneous Urticaria with Autoreactivity: A Preliminary Study.
Chen Q; Luo J; Yang X; Chen W; Liu W; Song Z
Int Arch Allergy Immunol; 2024; 185(2):190-195. PubMed ID: 37952519
[TBL] [Abstract][Full Text] [Related]
14. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
16. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
[No Abstract] [Full Text] [Related]
17. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
18. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
19. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria.
Kolkhir P; Pogorelov D; Olisova O
Eur Ann Allergy Clin Immunol; 2017 Jul; 49(4):189-192. PubMed ID: 28752724
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
